News >

10-Year Trabectedin Real-World Data Demonstrate Efficacy in Sarcoma

Jason Harris
Published: Wednesday, Jul 26, 2017

Treatment-related discontinuation rates were 7% in the dacarbazine arm and 10% in the trabectedin arms. There were treatment-associated deaths within 30 days of the last dose among 3.2% of patients receiving trabectedin compared with none in the dacarbazine arm.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Publication Bottom Border
Border Publication
x